B-cell therapy biotech Walking Fish closes down
May 7, 2024 · That asset, WFX-001, was most recently in IND-enabling studies, according to Walking Fish’s website. The biotech intended to reconfigure B cells to help build proteins, including a deficient ...
Rising Costs Lead to Closure of Cell Therapy Biotech Walking Fish
May 8, 2024 · Walking Fish had been working on a three-asset portfolio of B-cell-based therapies, with a lead candidate aimed at treating Fabry disease. The biotech’s main asset, WFX-001, was in the final …
WFX-001 - Drug Targets, Indications, Patents - Synapse
May 7, 2025 · That asset, WFX-001, was most recently in IND-enabling studies, according to Walking Fish’s website. The biotech intended to reconfigure B cells to help build proteins, including a deficient …
Autologous B-cell therapy WFX-001 corrects systemic α-GAL
Feb 14, 2024 · Walking Fish Therapeutics Inc. presented a new first-in-class autologous B-cell therapy, named WFX-001, being developed for the treatment of Fabry disease.
Repetidor Extensor De Wifi 300mbps Oryx WF001 - Frávega
- Máxima seguridad WLAN con WPA2, WPA, WPA y WEP (128/64). Aprovechá las ofertas y cuotas disponibles en productos seleccionados. Encontralos en nuestra tienda online o en la sucursal más …
WFX-001 (WFX-001) - 药物靶点：GALA_在研适应症：法布里病_专利_ …
May 7, 2025 · That asset, WFX-001, was most recently in IND-enabling studies, according to Walking Fish’s website. The biotech intended to reconfigure B cells to help build proteins, including a deficient …
一家细胞治疗企业，关闭_腾讯新闻
May 10, 2024 · 目前WFT旗下有三款处于临床前阶段的在研药物，其中一个主要候选药物是WFX-001，用于法布里病治疗，最近处于IND阶段，还有2个研发项目WFX-002和WFX-003 ...
High costs, investor exit prompt closure of cell therapy biotech ...
Aug 21, 2024 · That asset, WFX-001, was most recently in IND-enabling studies, according to Walking Fish’s website. The biotech intended to reconfigure B cells to help build proteins, including a deficient …
MaxCyte Signs Strategic Platform License with Walking Fish …
May 4, 2023 · Walking Fish’s first program, WFX-001 employs B cells as protein factories to generate a deficient enzyme in Fabry disease.
Walking Fish Therapeutics - gosset.ai
Their first program, WFX-001, was aimed at Fabry disease. The company closed down in May 2024 after a lead investor backed out of a critical Series B funding round.
Skip to content